Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II Sells 2,633 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 2,633 shares of the company’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $36,862.00. Following the completion of the transaction, the chief financial officer now owns 232,485 shares in the company, valued at $3,254,790. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Day One Biopharmaceuticals Stock Up 1.2 %

Shares of DAWN opened at $14.09 on Tuesday. Day One Biopharmaceuticals, Inc. has a 12-month low of $9.67 and a 12-month high of $18.07. The business’s fifty day moving average is $14.07 and its 200 day moving average is $14.79. The stock has a market cap of $1.23 billion, a P/E ratio of -5.61 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.70. The company had revenue of $8.19 million for the quarter, compared to the consensus estimate of $0.90 million. On average, analysts expect that Day One Biopharmaceuticals, Inc. will post -2.29 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on DAWN shares. Bank of America upgraded shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and upped their price target for the company from $11.00 to $24.00 in a research note on Thursday, August 1st. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, August 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, July 30th. Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $35.71.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Quintet Private Bank Europe S.A. increased its holdings in Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares during the last quarter. Arizona State Retirement System increased its holdings in Day One Biopharmaceuticals by 8.2% in the 4th quarter. Arizona State Retirement System now owns 13,373 shares of the company’s stock worth $195,000 after acquiring an additional 1,010 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in Day One Biopharmaceuticals by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock worth $979,000 after acquiring an additional 1,445 shares during the last quarter. ProShare Advisors LLC grew its holdings in Day One Biopharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock valued at $287,000 after buying an additional 1,447 shares in the last quarter. Finally, Quest Partners LLC purchased a new position in Day One Biopharmaceuticals during the 4th quarter valued at about $29,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.